Stockscreener 앱 받기
58.78
0.56%
0.33
Arcellx Inc 주식(ACLX)의 최신 뉴스
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks
Arcellx Announces Positive Phase 2 Study Results - TipRanks
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace
Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks
Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com
Arcellx Inc.: Strong Financial Position and Promising Phase 2 Study Outcomes Drive Buy Rating - TipRanks
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Here’s Why Arcellx (ACLX) Declined in Q1 - Insider Monkey
Piper Sandler Remains a Buy on Arcellx Inc (ACLX) - The Globe and Mail
Arcellx Inc (ACLX) Receives a Buy from Scotiabank - The Globe and Mail
Arcellx First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcellx (ACLX) Maintains Rating as Price Target is Lowered by Sc - GuruFocus
Arcellx price target lowered to $93 from $133 at Scotiabank - TipRanks
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Promising Potential of Arcellx Inc’s Anito-cel Therapy: A Buy Rating Backed by Positive Study Data and Strategic Trial Enhancements - TipRanks
Arcellx (ACLX): Scotiabank Adjusts Price Target Amid Regulatory Concerns | ACLX Stock News - GuruFocus
Arcellx’s Promising Trial Results and Strategic Partnerships Justify Buy Rating with $121 Target - TipRanks
Arcellx Inc. Receives Buy Rating: Strong Financial Outlook and Promising Data Catalysts - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Program Drives Buy Rating - TipRanks
ARCELLX Earnings Results: $ACLX Reports Quarterly Earnings - Nasdaq
Earnings Flash (ACLX) ARCELLX INC. Reports Q1 Revenue $8.1M, vs. FactSet Est of $19.5M - marketscreener.com
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire
Before Buying Arcellx Inc (NASDAQ: ACLX) Stock, Read This First - Stocksregister
Arcellx, Inc. (NASDAQ:ACLX) Stake Reduced by Envestnet Asset Management Inc. - Defense World
Investor’s Toolkit: Key Ratios for Assessing Arcellx Inc (ACLX)’s Performance - DWinneX
Dimensional Fund Advisors LP Buys 186,013 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx (ACLX) to Release Quarterly Earnings on Thursday - Defense World
Arcellx Enters Oversold Territory (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Shares Acquired by Invesco Ltd. - Defense World
(ACLX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Wells Fargo & Company MN Has $2.04 Million Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
William Blair Sticks to Its Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying - EMEA Tribune
Alliancebernstein L.P. Sells 6,181 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
(ACLX) Proactive Strategies - news.stocktradersdaily.com
Wellington Management Group LLP Trims Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Insider Selling: Arcellx, Inc. (NASDAQ:ACLX) Director Sells 1,500 Shares of Stock - MarketBeat
Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential - Insider Monkey
Arcellx (NASDAQ:ACLX) Trading Down 6.8% on Insider Selling - Defense World
Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset - MSN
Arcellx director Kavita Patel sells shares worth $86,250 By Investing.com - Investing.com Australia
Sei Investments Co. Purchases 4,827 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx director Kavita Patel sells shares worth $86,250 - Investing.com
29,446 Shares in Arcellx, Inc. (NASDAQ:ACLX) Purchased by American Century Companies Inc. - Defense World
Vanguard Group Inc. Grows Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Stake Lessened by Corebridge Financial Inc. - Defense World
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Benzinga
1.54%
7.58%
자본화:
|
볼륨(24시간):